Press Release – March 13, 2023
Announcing new Editor-in-Chief of CellR4: Prof. Monica Montopoli
CellR4 is proud to announce the new Editor-in-Chief Prof. Monica Montopoli in collaboration with Dr. Marco Infante as Managing Editor.
Verduci Editore is deeply grateful to Dr. Ekaterine Berishvili for her service and contribution to the growth of CellR4 over the past years. She gave valuable input in thriving the scientific popularization of the journal.
Prof. Montopoli obtained her master’s degree in Pharmaceutical Chemistry and Technology in 2003 at the University of Padua. In 2007, she received her Ph.D in Molecular and Cellular Pharmacology, international collaboration with the University of Padua, Leopold-Franzens Universitat, Innsbruck e Albert-Ludwigs Universitat, Freiburg. In 2013 she obtained a master’s degree in “Gender health and medicine” at the University of Florence. In 2019, she worked as a scientific collaborator for AIRC project (Italian Association for Cancer Research) and for the PRIN project promoted by the Italian Ministry of Education, University and Research (MIUR). She is also a full member of the Italian Society of Pharmacology (SIF) and Italian Society of Toxicology (SiTox) and of the Board of Directors of the Italian Society of Phytotherapy (SiFit). She is the coordinator of the phytotherapy committee in the clinical oncology working group of the Italian Phytotherapy Society (SIFiT). Prof. Montopoli is one of the founders of the Metabolism Meets Function group-MMF (a collaboration between Unipd, Unito, and Uniba) in the field of tumor metabolism. Her research activity is funded by public institutions and private companies and is documented by more than 85 peer-reviewed papers, more than 110 posters and several invited lectures to national/international conferences and meetings. Thanks to her cancer research, she was selected as the protagonist in the “Women in Science” 2019, 2020, 2021 edition (Unipd, Vimm) events. Prof. Monica Montopoli is Associate Professor of Pharmacology at the Department of Pharmaceutical and Pharmacological Sciences, School of Medicine, University of Padua, Italy, and Associate Investigator at Veneto Institute Molecular Medicine (VIMM), Padua, Italy. She is visiting scientist at the Institute of Oncology Research in Bellinzona, Switzerland.
Under her new editorship and vision, CellR4 continues to welcome articles covering topics spanning from pharmacological studies to cell-based therapies, organ replacement therapies, tissue engineering, cellular reprogramming mechanisms and technologies, and regenerative pharmacology.
Press Release – September 22, 2021
Announcing new Editor-in-Chief of CellR4: Dr. Ekaterine Berishvili
CellR4 is proud to announce the new Editor-in-Chief Dr. Ekaterine Berishvili. Dr. Berishvili obtained her MD and PhD degrees in Tbilisi, Georgia, in 1999 and 2003. Between 2003 and 2014, she held research fellow and visiting professor positions at the Diabetes Research Institute, University of Miami (Prof. Camillo Ricordi) and at the Albert Einstein College of Medicine, New York (Prof. Sanjeev Gupta). She was promoted associate professor at Tbilisi State Medical University (2008-2014) and is currently holding an associate professorship at Ilia State University, in Tbilisi. She has been working as a scientific collaborator in the department of surgery at the University of Geneva since 2014, and was appointed in 2020 as a leader of research group of Tissue Engineering and Organ Regeneration in the Department of Surgery. She serves as a Councillor of European Society for Organ Transplantation(2021-2025) and as an Associate Editor of Transplant International. Dr. Berishvili is coordinating scientific consortium funded by the H2020 program. She is also a member of the Juvenile Diabetes Research Foundation (JDRF) beta cell replacement consortium.
Under her new editorship and vision, CellR4 continues to welcome articles covering topics spanning from cell-based therapies to organ replacement therapies, solid organ and cell transplantation, tissue engineering, cellular reprogramming mechanisms and technologies, and regenerative pharmacology.
Press Release – February 1, 2021
CellR4 indexed in DOAJ
We are glad to announce that CellR4 has just been indexed in the Directory of Open Access Journals (DOAJ) thanks to the remarkable improvements that have been made in the journal’s quality over the last few years. DOAJ is a well-known community-curated online directory that indexes and provides access to high quality, open access, peer-reviewed journals (https://doaj.org/).
Press Release – January 5, 2021
Groundbreaking trial sheds light on the safety and effectiveness of umbilical cord-derived mesenchymal stem cells for COVID-19 treatment
Prof. Camillo Ricordi and other researchers affiliated with University of Miami Miller School of Medicine and The Cure Alliance led a groundbreaking phase 1/2a, randomized controlled trial showing that umbilical cord-derived mesenchymal stem cell (MSC) infusions safely reduce risk of death and quicken time to recovery for patients with severe COVID-19, according to results published in STEM CELLS Translational Medicine in January 2021. The protocol of this trial was previously published in CellR4 in April 2020: Lanzoni et al., Umbilical cord-derived mesenchymal stem cells for COVID-19 patients with acute respiratory distress syndrome (ARDS). CellR4 2020; 8: e2839. DOI: 10.32113/cellr4_20204_2839.
Press Release – January 7, 2020
A New Managing Editor for CellR4
CellR4 was launched in 2013 by Prof. Camillo Ricordi (Founder of The Cure Alliance) with the aim of providing a platform for discussion of challenges and opportunities in the development of new treatments, independent from the disease target (a unique feature of top-class medical journals). CellR4 was created with true Open Access character, the full text of articles being downloaded free of charge by readers.
The Editor-in-Chief Prof. Camillo Ricordi has now asked the experienced researcher Dr. Marco Infante to join him in the next phase of CellR4 development as the new Managing Editor of our journal.
CellR4 will continue to focus on cellular events in the study and treatment of disease, with the emphasis on cellular repair, replacement, regeneration and reprogramming. Papers dealing with all types of disease or conditions – irrespective of cause, organ system or classification – are welcome, with an emphasis on translational aspects concerning areas of unmet clinical needs and diseases so far considered as incurable. Dr. Infante is actively encouraging high-level opinion and perspectives papers as well as those that cover original research and/or clinical methods.